Clinical Value of rhBNP in the Treatment of Patients with Stanford Type B Aortic Dissection

Abstract

Objective: To determine the clinical value of rhBNP in the treatment of patients with Stanford type B aortic dissection. Methods: From June 2018 to October 2021, 162 patients with Stanford type B aortic dissection were selected from the Cardiology Department of Henan Provincial Chest Hospital and randomly divided into two groups: control group (81 patients) and observation group (81 patients). The patients in the control group were treated with conventional therapy. On the basis of the control group, the patients in the observation group were treated with rhBNP. The cardiac function, renal function, pulmonary function, and inflammatory indices before and after treatment for 72 hours, as well as the incidence of adverse reactions between the two groups were compared. Results: After treatment, the cardiac function (LVEF and NT-pro BNP), renal function (urine output for 24 hours, Scr, and Cys-C), pulmonary function (PaO2, SPO2, and PaO2/FiO2), and inflammatory (IL-6, hsCRP, and MCP-1) indices of the observation group improved significantly compared to those of the control group (p < 0.05). Conclusion: rhBNP can improve cardiac function, renal function, and pulmonary function, as well as alleviate inflammation in patients with Stanford type B aortic dissection. Hence, in the treatment of patients with Stanford type B aortic dissection, rhBNP provides multi-organ protection.